文献速递艾滋病与性传播感染

英国HIV-1近期感染中传播性整合酶链转移抑制剂耐药监测

Surveillance of HIV-1 transmitted integrase strand transfer inhibitor resistance in the UK.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

该研究对2014至2016年英国655例近期HIV-1感染者进行超深度测序,检测整合酶、蛋白酶和逆转录酶耐药相关突变。结果显示无样本在高变异频率(≥20%)下携带主要整合酶耐药突变,仅3.9%样本以低频变异(2%-20%)形式出现,而8.0%样本在高频率下携带逆转录酶抑制剂和蛋白酶抑制剂主要耐药突变。建议继续监测新诊断患者的传播性整合酶耐药。

要点

  • 近期感染人群中主要整合酶耐药突变罕见,仅以低频变异形式出现。
  • 逆转录酶抑制剂和蛋白酶抑制剂主要耐药突变高频检出率为8.0%。
  • 建议持续监测新诊断患者的传播性整合酶耐药以指导临床实践。

核心结论

  • 2014至2016年间,近期HIV-1感染成人中主要整合酶耐药突变不常见,仅以临床意义存疑的低频变异形式出现。

研究设计与样本

  • 研究采用近期感染检测算法识别英国新诊断的近期(4个月内)HIV-1感染,随机选取655例(中位年龄33岁,95%男性,83%MSM,78%白人),样本来自2014至2016年(分别为320、138和197例),通过超深度测序检测整合酶、蛋白酶和逆转录酶耐药相关突变。

主要发现

  • 无样本在高变异频率(≥20%)下携带主要整合酶耐药相关突变。
  • 25/640(3.9%)样本仅以低频变异(2%-20%)形式携带主要整合酶耐药相关突变。
  • 47/588(8.0%)样本在高频率下携带主要逆转录酶抑制剂和蛋白酶抑制剂耐药相关突变。

临床怎么用

  • 近期感染人群中主要整合酶耐药突变罕见,支持现有治疗指南中对整合酶耐药检测的常规推荐可继续评估。
  • 持续监测新诊断患者的传播性整合酶耐药有助于更新临床实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: HIV treatment guidelines have traditionally recommended that all HIV-positive individuals are tested for evidence of drug resistance prior to starting ART. Testing for resistance to reverse transcriptase inhibitors and PIs is well established in routine care. However, testing for integrase strand transfer inhibitor (InSTI) resistance is less consistent. OBJECTIVES: To inform treatment guidelines by determining the prevalence of InSTI resistance in a national cohort of recently infected individuals. PATIENTS AND METHODS: Recent (within 4 months) HIV-1 infections were identified using a Recent Infection Testing Algorithm of new HIV-1 diagnoses in the UK. Resistance-associated mutations (RAMs) in integrase, protease and reverse transcriptase were detected by ultradeep sequencing, which allows for the sensitive estimation of the frequency of each resistant variant in a sample. RESULTS: The analysis included 655 randomly selected individuals (median age = 33 years, 95% male, 83% MSM, 78% white) sampled in the period 2014 to 2016 and determined to have a recent infection. These comprised 320, 138 and 197 samples from 2014, 2015 and 2016, respectively. None of the samples had major InSTI RAMs occurring at high variant frequency (≥20%). A subset (25/640, 3.9%) had major InSTI RAMs occurring only as low-frequency variants (2%-20%). In contrast, 47/588 (8.0%) had major reverse transcriptase inhibitor and PI RAMs at high frequency. CONCLUSIONS: Between 2014 and 2016, major InSTI RAMs were uncommon in adults with recent HIV-1 infection, only occurring as low-frequency variants of doubtful clinical significance. Continued surveillance of newly diagnosed patients for evidence of transmitted InSTI resistance is recommended to inform clinical practice.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Mbisa JL, Ledesma J, Kirwan P, et al. Surveillance of HIV-1 transmitted integrase strand transfer inhibitor resistance in the UK. J Antimicrob Chemother. 2020. PMID: 32728703. doi:10.1093/jac/dkaa309

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。